G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and fruitful, because the predictable routine of meetings, deadlines, and the like is now upon us. There is only one thing to do when confronted with such a situation — reach for a cup of stimulation. Our flavor today is macadamia nut, for those keeping track. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to get you started. Hope you have a smashing day and do keep in touch …

Sanofi (SNY) agreed to pay $4.8 billion to buy Ablynx (ABLYF), outbidding Novo Nordisk (NVO) for a drug to treat a rare blood clotting disorder, The Wall Street Journal notes. This is the second deal this month for Sanofi, which is paying $11.6 billion for Bioverativ (BIVV) and its hemophilia treatments. Sanofi has been under pressure from investors after losing out on two attempted takeovers — Medivation and Actelion Pharmaceuticals — in 2016.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.